|Kurma Partners||Managing Partner||fr|
How to spark the interest of VCs for Series A financing?
harmacist, doctor in pharmacology, Insead MBA. After his dissertation, Thierry was a scientific representative for Laboratoires Fournier in Japan for four years at a time when Lipanthyl was released in Japan and research programmes were being rolled out with Grelan, a Takeda Group company. Having then studied at Insead, he joined Flamel Technologies as project director for Pharmaceutical R&D, after its IPO on the Nasdaq. In 1998, he then moved to the investment world, first at Caisse des Dépôts (CDC Innovation, then within the PharmaVent project), before moving to AGF Private Equity, where he supervised the healthcare investment team